Baker BROS. Advisors LP Sells 1,010,132 Shares of Compass Therapeutics, Inc. $CMPX

Key Points

• Baker BROS. Advisors LP decreased its stake in Compass Therapeutics by 64.9%, now holding 547,498 shares valued at approximately $1,040,000.
• Several institutional investors, including Wells Fargo & Company and Renaissance Technologies LLC, increased their positions in Compass Therapeutics during the fourth quarter.
• Analysts have rated Compass Therapeutics with an average of "Buy" and set a consensus price target of $12.89, with individual price objectives up to $32.00.

Baker BROS. Advisors LP reduced its holdings in Compass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) by 64.9% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 547,498 shares of the company's stock after selling 1,010,132 shares during the period. Baker BROS. Advisors LP owned about 0.40% of Compass Therapeutics worth $1,040,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of CMPX. Enavate Sciences GP LLC purchased a new stake in Compass Therapeutics in the 4th quarter worth about $11,293,000. Tang Capital Management LLC lifted its stake in Compass Therapeutics by 225.4% in the 4th quarter. Tang Capital Management LLC now owns 5,900,000 shares of the company's stock worth $8,555,000 after acquiring an additional 4,087,005 shares in the last quarter. MPM Bioimpact LLC lifted its stake in Compass Therapeutics by 51.9% in the 4th quarter. MPM Bioimpact LLC now owns 8,567,896 shares of the company's stock worth $12,423,000 after acquiring an additional 2,926,002 shares in the last quarter. SG Americas Securities LLC lifted its stake in Compass Therapeutics by 138.2% in the 1st quarter. SG Americas Securities LLC now owns 940,784 shares of the company's stock worth $1,787,000 after acquiring an additional 545,767 shares in the last quarter. Finally, Nuveen LLC purchased a new stake in Compass Therapeutics in the 1st quarter worth about $579,000. 68.43% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on CMPX shares. Raymond James Financial raised Compass Therapeutics to an "outperform" rating and set a $9.00 price target for the company in a research note on Tuesday, July 1st. D. Boral Capital reaffirmed a "buy" rating and issued a $32.00 target price on shares of Compass Therapeutics in a report on Tuesday, August 12th. Finally, Guggenheim lifted their price objective on Compass Therapeutics from $10.00 to $12.00 and gave the stock a "buy" rating in a report on Tuesday, August 12th. One equities research analyst has rated the stock with a Strong Buy rating and nine have given a Buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Buy" and an average target price of $12.89.

Compass Therapeutics Stock Performance

NASDAQ:CMPX traded up $0.07 on Friday, reaching $3.44. The company's stock had a trading volume of 388,871 shares, compared to its average volume of 1,386,189. Compass Therapeutics, Inc. has a 1-year low of $1.27 and a 1-year high of $4.08. The firm has a market cap of $475.68 million, a PE ratio of -7.64 and a beta of 1.50. The business's 50-day moving average price is $3.01 and its two-hundred day moving average price is $2.47.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last posted its earnings results on Monday, August 11th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.01). As a group, sell-side analysts expect that Compass Therapeutics, Inc. will post -0.36 EPS for the current year.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.